title: The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy.
abstract: This prospective study was undertaken to evaluate the efficacy of continuous-infusion doxorubicin and cisplatin (CI-DOX/CPPD) for the treatment of children with incompletely resected hepatic cancer. Of the 46 evaluable patients, 32 had hepatoblastoma (70%) and 14 had hepatocellular carcinoma. Ten children had stage II tumors (microscopic residual), 25 were defined as stage III (gross residual), and 11 had distant metastasis (stage IV). Twelve patients underwent initial incomplete resection of their hepatic lesions and in the 34 others tumor biopsy specimens were obtained. Chemotherapy was administered and the majority of the children (70%) had an excellent clinical response with a decrease in both alpha-fetoprotein levels and measured tumor dimensions. The combination of CI-DOX/CPDD clearly facilitated surgical management, allowing for delayed hepatic resections in 20 of the 34 patients (59%) whose tumors were initially biopsied and considered to be unresectable. Overall survival in this study demonstrates a significant improvement in comparison to the historical controls. Twenty-one patients (46%) remain in complete clinical remission an average of 30 months following diagnosis (range, 17 to 40 months). The outcome of the children with hepatoblastoma was much better than those with hepatocellular carcinoma (63% v 17% survival). Survival of the 20 children who underwent delayed hepatic resections was not statistically different from the 12 patients whose hepatic tumors were removed at the initial laparotomy (41% v 58% survival). Although no obvious survival advantage was observed in those patients who underwent initial hepatic resections, there did appear to be an increased risk of postoperative complications in children whose tumors were resected following chemotherapy (8% v 25%).
authors.affiliation: Childrens Cancer Study Group, Pasadena, CA 91101.
authors.forename: D R
authors.initials: DR
authors.lastname: King
authors.forename: J
authors.initials: J
authors.lastname: Ortega
authors.forename: J
authors.initials: J
authors.lastname: Campbell
authors.forename: J
authors.initials: J
authors.lastname: Haas
authors.forename: A
authors.initials: A
authors.lastname: Ablin
authors.forename: D
authors.initials: D
authors.lastname: Lloyd
authors.forename: K
authors.initials: K
authors.lastname: Newman
authors.forename: J
authors.initials: J
authors.lastname: Quinn
authors.forename: M
authors.initials: M
authors.lastname: Krailo
authors.forename: J
authors.initials: J
authors.lastname: Feusner
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008297:Male; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D004317:Doxorubicin; D002945:Cisplatin